Thomas Gibbs
Director @ Debiopharm Innovation Fund
Thomas Gibbs is a Series B investor at Debiopharm Innovation Fund focused on Biotechnology and Medical Device. Thomas Gibbs received his bachelor's degree science in applied biology from the University of Wales Institute of Science and Technology, and earned his doctor's degree in philosophy in microbial genetics at the University of Warwick. He has spent more than two decades in the commercialization of life science technologies, split equallybetween the pharmaceutical industry and scientific tool developers. He has been responsible for a wide range of activities including quality assurance, operations, late-stage product development and marketing, and increasingly business development. He has broad experience in both startups such as Cytion, Covalys, and Med Discovery and more established companies such as Delta Biotechnology, Molecular Devices, and Debiopharm in Europe and the United States of America. He joined Debiopharm International in 2012.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Thomas Gibbs invests in
Stages Thomas Gibbs invests in
Countries Thomas Gibbs invests in
Investment Focus
Industry
- Biotechnology 1 (33%)
- Medical Device 1 (33%)
- Health Diagnostics 1 (33%)
Stage
- Series B 1 (33%)
- Series C 1 (33%)
- Series D 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Biocartis Group NV
|
Biocartis SA, a molecular diagnostics company, develops diagnostics technology platform for multiplexed detection of bio-analytes. It focuses on integrated molecular and immunodiagnostics based on its proprietary micro-technology platform. The company develops and licenses a series of technologies to build a diagnostics platform for multiplexeddetection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. Its products are used for various applications, including analysis of bio-molecules associated with risks factors, early detection, staging, treatment selection, and monitoring of a disease. Biocartis SA was founded in 2007 and is based in Lausanne, Switzerland. | $37.8M / Series D / Dec 12, 2012 | |
|
Biocartis Group NV
|
Biocartis SA, a molecular diagnostics company, develops diagnostics technology platform for multiplexed detection of bio-analytes. It focuses on integrated molecular and immunodiagnostics based on its proprietary micro-technology platform. The company develops and licenses a series of technologies to build a diagnostics platform for multiplexeddetection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. Its products are used for various applications, including analysis of bio-molecules associated with risks factors, early detection, staging, treatment selection, and monitoring of a disease. Biocartis SA was founded in 2007 and is based in Lausanne, Switzerland. | $77.9M / Series C / Nov 17, 2011 | |
|
Biocartis Group NV
|
Biocartis SA, a molecular diagnostics company, develops diagnostics technology platform for multiplexed detection of bio-analytes. It focuses on integrated molecular and immunodiagnostics based on its proprietary micro-technology platform. The company develops and licenses a series of technologies to build a diagnostics platform for multiplexeddetection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. Its products are used for various applications, including analysis of bio-molecules associated with risks factors, early detection, staging, treatment selection, and monitoring of a disease. Biocartis SA was founded in 2007 and is based in Lausanne, Switzerland. | $32.9M / Series B / Apr 08, 2010 |
Co-Investors
About Debiopharm Innovation Fund
Debiopharm Innovation Fund invests in digital health companies that have an impact on cancer, infectious diseases, and drug development. We are looking for ambitious entrepreneurs raising series A or B with clinically proven, transformative technologies that use AI and data to help patients. We do not invest in consumer wellness or workflowsolutions. Our initial investment is typically $2-5M. Along with capital we bring deep pharma knowledge & networks and long-term commitment to help build value in your company. We are an evergreen investment fund of the pharmaceutical company Debiopharm based in Lausanne, Switzerland.
Debiopharm Innovation Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Cedric Odje
Senior Investment Associate
|
|||
|
Nicole Wilson
Senior Administrative Assistant
|
|||
Tanja Dowe
Chief Executive Officer
|
|||
|
Thomas Gibbs
Director
|
|||
Vincent Lepreux
Investment Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Thomas Gibbs invest in?
Thomas Gibbs invests primarily in Biotechnology, Medical Device and Health Diagnostics startups, most often at Series B and Series C stage. Most of the 3 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Thomas Gibbs last invest?
The most recent investment recorded for Thomas Gibbs closed in Dec 2012. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
